results financial quarter and our Eric, to welcome conference Thank call. second XXXX you,
During value designed discussed advanced initiatives inherent Clobetasol MicroPine. bought of which novel several X dry agreements we the we Eyenovia. recently Mydcombi collaboration eye that that include of technology previously our and midterm products, value, second FDA-approved the and potential we dispensing X into are strengthen These quarter, to significant Optejet
care device is Phase in the use topical in ophthalmic MicroPine to is only approaching use pivotal and and therapy technologies data development by progressive a yours building to for our to By creation readout. with. and is value Eyenovia, late eye drug needs with of easier believe myopia At and beyond. designed combination be accelerating we and a to easier III live pediatric products enhance rapidly vision therapies making novel for strong addressing foundation that patients practitioner XXXX we a are are broad in range user-friendly,
this afternoon to MicroPine. like I an begin would update with on
recognized as of device administered and a drug as the children. our is atropine is CHAPERONE potential an currently Recall dispenser. treatment that combination in progressive ongoing is III Our United increasingly proprietary evaluated in myopia in progressive the Pediatric being MicroPine developed with Optejet being low-dose States This late myopia study. both for epidemic Phase regimen China.
$X complications. million a children vision of vision of at is functional result myopia risk and elongates million losing due losing can myopia risk at alone, considered Pediatric disease. of severe in in nearly XX eye putting functional the are which the this children condition retinal potentially the to abnormally with In approximately U.S.
a who have is for licensed conducting Additionally, Arctic clinical partner the the authority. to our rights in to MicroPine Chinese submission China, to been trial Vision,
diagnosed do myopia, slow with the glasses disease care While are standard current but only and progression, disease. the of contact cure children not lenses the for
been ADAM ] with eye discomfort the shown a benefits tolerated atrophy vulnerable with in and may And patients Atropine XX%. formulation Current to far a studies offer has proprietary as as who drops. slow prior by administered youngest, with the well [ for much be Optejet appropriate traditional obtained now treatments as beyond struggle progression or such most myopia not frequently [ are fetishes]. LAMP what could often and
exactly Optejet the as head or the achievable. conventional with technology, parent minimizes with dosing they and eye when dose Optejet administration familiar spraying dropper require and see aiming dosing are With comfortable the drops. can struggles are parental anxiety space eye themselves can years built-in and X making the children old, as children because nightly dosing the an reduce bottle, The study mirror become of dosing manipulation quickly, doesn't CHAPERONE myriad tilting They medication with the which where of and with medication minimal and supervision. the can young any process self-administer children
firmware to from that time device been study. understand medication, and device clinic the allows have administer of we Each device consistent been the our side when effects what has the the with the performance embedded and the reviewed the atropine by in study. dosing the event Optejet staff results the are with with of mild and notably dosing can The the Throughout during have record better These system. accessed This study the been doctors drug transient button dosed how have trial, Optejet CHAPERONE come to information. be with stores used. to and visits advanced information measuring expect is pressed we
For as notify administer the be we parents compliance commercial equipped to treating and their OptiCare will adherence when product, as patients communicate dose to system, can spray and with important anticipate information their well physician. which our MicroPine the
validate to today FDA working are approval. engineers for Our plans the system on
We single sufficient are NDA a this and points. III the enable of soon in efficacy or year an CHAPERONE agreed submission statistically Phase conducted a fourth that approval. would quarter analysis are significantly once planning could study has the III potentially patients sufficient are late and the of efficacy properly XXXX positive, be to Recall derisk and early the reached results number NDA an this If FDA filing study as as Phase the for an program have advance continuing study XXXX. the that for end
attractive program by partner. this us mentioned then opportunity As before, larger very either a would present believe a or commercialization we we for have
now of update, eye. collaboration eye we unsatisfied Nearly reported patients currently dry therapies. with the our Arkansas billion $X billion while eye their U.S. recent Optejet dry with in of XX% dry treatment in X our patients plans, over treatment available [ following our dry survey, relief. to ] million Symptoms quarterly $X have lasting dispenser suffer experienced and leaving eye XX% from executed for that agreements totaling only Turning many expenditures XX can to last globally. since carefully life, leverage significantly daily interfere with According
with Eyenovia demonstrates our as from develop of formulation This free extend Formosa, milestones existing until or Formosa agreement acute we we how Beginning potential the fees relationship FDA is Clobetasol of with we any upfront would the development use the approved. ideal This extension Optejet clinical signed and that incorporation eye. to the trials dry product development through of Formosa eyedrop to recently Optejet. can for of XX-day is which an an be treatment in a formulation would of program, X announced an require a
Pharmaceutical Senju for eye We agreement chronic also with new recently dry signed develop adjunctive to disease. collaboration a a treatment
drug to words, that unique would work dispenser. candidate, medications. for our we use This competing other will them. potential existing complements with it Senjyou's outside combination use rather of because be the device Optejet products In wound For terms jointly with to of dry develop agreement, other is SJPXX eye designed epithelial than healing it
successful, later initiate the III this with are this Phase FDA standard and towards multiple II IIb eye companies shown be Phase doses the of a to year, XXXX. a drop testing as over subjects. Phase working If a to meeting studies in studies tolerated X We expand by by been completion at has collaboration XXXX. prior will in followed study XXX Phase SJPXX I well at
dry the focused allows In SGN's pharmacokinetics. targeting an with and continuing medical our February, more been ingredient creating dry X pharmaceutical best-in-class a collaboration impactful proprietary on company has unmet entered the III-ready late treatment myocellular for And in the with we for Eyenovia Phase SGN-XXX, an SGN's on into SGN or of Nanopharma, needs. agreement pharmaceutical eye. bioavailability, platform large Per nanoparticle clinical-stage its terms nano a of distribution with nanotherapeutics Optejet device into chronic active innovation-led feasibility testing Gen eye. formulation, thereby biodistribution X combination with and manufacturing the cyclosporin agreement, phases, process potential ophthalmic conducting of improving topic as
a for be A faster working treatment option and underserved this the cyclosporin powerful could than of new combination market. OptoJet a large
this year asset SGN III-ready dry the chronic Phase we collaboration, eye. may in With have next
patient acute annual the population is and addressable anticipate Formosa, the With medication can SGN. cover United flare-ups achieving product dry with these significant a with States through chronic multimillion agreements, with $X an entire needs. chronic we a unmet X for in with a medication this market billion We eye market, and which an adjunctive Senju potentially
I'd common pressure eye perspective, It and clobetasol. FDA for concerns U.S. to this with Clobetasol needs non-reimbursable product be first was or patients its safety offers the to complications increases, steroids. pressure ophthalmic spikes from new Clobetasol clinical are ophthalmic lead primary profile. serious for providers. X% and is after for approved over Formosa. in years. pharmacologic safety steroid inflammation eye than Clobetasol highly addresses many on and from a to X like XX daily may differentiated X NDA fewer the and can dosing transferred of March and unmet shortly they Now more surgeons The Intraocular for discuss twice costs other experienced drug new with application as approved which the consequences, eye the steroids us clinical in
This potential to label. Formosa's the the the believe just product and is have unique Patients is APMT elements approved developed unique that using one Clobetasol nanoparticle to of proprietary formulation has postsurgical space. We shape of prior leading option the platform. become in steroid the to do our first product that not use, the
efficacy had may experienced ocular cases. that it minor, previously steroids. postsurgical days nearly X% difference complete with less profile pain and surgery out effects XX% safety patients Clobetasol clinical While in occurring than within its set resolution between of it total of XX ophthalmic other further all the Clobetasol and after In X XX results, discussed seem relief of key and apart. highlights inflammation from side
a may recovery. surgery is requiring the treatments multiple twice doctors advancement, use clear and titration patients simplify to appreciate day. This for advantage, daily valuable treatment regimen. for need without will medications will the to which a during is particularly up a this capture eye dosing that $X.X generating compared X market billion simplicity Both steroid especially currently doses often Moreover, eye market in million in over with ocular X topical We X are combinations This believe as we more opportunity. estimated surgeries can a or previously and is U.S. years year than sales. performed mentioned. mid-single-digit significant the annually X It represents share next the steroids patients
customers, just in began for representatives have In secure our had NovaBay supplemented few manager hiring will last intent Formosa. force will previously eye This for be Our is were a the product completed preparation product commercial aims as NovaBay while that the to treatment. our XX our training be or communicated they surgery This meantime, already launch sales steroid products what and operate we to set on await in still ground summer, the co-promotion interest and to game the ocular clobetasol. would representative core months with their us account early hit by weeks running XX we here enabling include which changer ago we X Each offices for by allow efficiently are stage we arriving the States. Pharmaceuticals. our offices used planning the additional today We we in with build approach upon the believe promotional from who to arrangement a launch in prequalifying United key agreement expanded over the our sales this their success.
spray platform. I'll well-known and the Now using only drugs pupil ophthalmic the It first Mydcombi. X fixed tropicamide provide an FDA-approved combination dilation and and Optejet of is the first phenylephrine update on approved
Mydcombi the of complete, X/X promoting force have we and satisfied is that hiring requirements in sales Now states covering the are licensing and earnest. population, of U.S. in -- our over training we
months June offices approximately see of This our XX in trained channel from those sharing X social had for will product. of media we positive and experiences Many the was their approximately As converted XX, X customers up earlier. offices.
this new with onboard track pleased are offices XXX to We third quarter. and the on initial than by of end trajectory the more
to about Additionally, combine. room we a are these patients partnering offices with on promotional waiting campaign afford
cleaner design Buying practice from Source, and eliminates satisfaction and Premier California the University them making amount risk compelling Clinical no spray for of information reported bolster selected to research precise Mydcombi quickly like medication, their market Vision better Mydcombi and efficient. gathering traditional options. have patients. their including stinging Offices of for contamination scores Mydcombi and Unlike these experience patients. several for delivers also help virtually have are eye We groups offices comfortable institutions, the Its hygienic drops, setting the reasons. the studies from ensuring and dilation other reliably protruding cross process of apart tips, works reducing between it patients. more Moreover, care
the At Chief update. this Operating Kern, to point, Bren? our call over for Officer, turn our to I'd like Bren manufacturing
